<DOC>
	<DOCNO>NCT01925859</DOCNO>
	<brief_summary>To compare pharmacokinetic property two different dos EryDex ( dexamethasone sodium phosphate encapsulate erythrocyte ) give single infusion healthy volunteer , base plasma concentration dexamethasone .</brief_summary>
	<brief_title>EryDex Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Ages 1855 year , inclusive . 2 . If female , subject pregnant lactating , negative serum pregnancy test Screening Baseline ( checkin ) . 3 . If female childbearing potential* , subject agree donate ovum use one follow method contraception time sign informed consent 2 month infusion . 1 . Cap diaphragm spermicidal cream jelly + male condom spermicide . 2 . Hormonal contraceptive ( oral , implant , injection patch ) + male condom spermicide . 3 . Intrauterine device + male condom spermicide . 4 . Vaginal ring + male condom spermicide . Nonchildbearing potential defined surgical sterilization ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) , hysterectomy least 3 month start study , postmenopausal ( define continuous amenorrhea least 2 year ) . 4 . If male , subject agree donate sperm use barrier contraception ( e.g. , condom spermicidal cream jelly ) time sign informed consent 2 month infusion . 5 . Physically mentally healthy , confirmed medical history , physical examination , vital sign , clinical laboratory test , ECG . 6 . The subject body weight least 45 kg body mass index â‰¤ 30 . 7 . Written inform consent participate obtain subject . 8 . Ability understand aim trial comply study procedure . General 1 . Females childbearing potential , pregnant , breastfeed . Women childbearing potential use two form birth control ( e.g . barrier hormonal ) eligible . 2 . Loss/removal 500 mL blood within past 4 week . 3 . A disability may prevent subject complete study requirement . 4 . Noncompliance study requirement . Medical History 5 . Current previous neoplastic disease . 6 . History impairment immunological system . 7 . History drug alcohol abuse ( within past 5 year ) . 8 . A current diagnosis severe unstable cardiovascular disease ; 9 . Any history current evidence cardiac illness determine investigator ; 10 . History current diagnosis psychiatric illness ( DSMIVTR Axis I diagnosis ) neurodegenerative disorder . 11 . Smoker ; currently time last 6 month . 12 . Hemoglobinopathy G6PD deficiency . 13 . History recurrent chronic infection , include Staphylococcus methicillinresistant Staphylococcus aureus ( MRSA ) . 14 . History positive tuberculosis skin test ( PPD test ) . Current Medical Status 15 . Have significant disease condition Investigator 's opinion would put subject risk participate trial . 16 . Vital sign outside follow range : 1 . Systolic blood pressure &lt; 90 &gt; 140 mmHg 2 . Diastolic blood pressure &lt; 50 &gt; 90 mmHg 3 . Pulse &lt; 50 &gt; 90 bpm . Patients pulse rate &lt; 50 otherwise healthy eligible trial approve Sponsor . 17 . Any clinically significant ECG abnormality , include disorder rate , rhythm , conduction , morphological change . 18 . Any clinically significant abnormality standard laboratory examination ( hematology , biochemistry , urinalysis ) , determine Investigator , consultation Sponsor . 19 . History hepatitis B and/or C , and/or positive serology result , indicate presence hepatitis B and/or C ( Hepatitis B surface antigen and/or antibody Hepatitis C ) . 20 . Positive result HIV serology . 21 . Positive result drug alcohol test screen and/or checkin unit . Alcohol intake limit 2 drink per day 2 week prior dose ; alcohol consumption prohibit time 22 . Clinically significant abnormal serum cortisol level ( normal range &gt; 1.5x ULN ) screening . Prior/Concomitant Medication 23 . Any previous steroid consumption within 4 week Baseline . 24 . Chronic condition prior allergic reaction represent contraindication use steroid drug . 25 . Have participate trial investigational drug receive dose within 30 day 10 halflives ( whichever great ) start Screening Period . 26 . Requirement prescription overthecounter ( OTC ) medication , hormonal birth control occasional use acetaminophen , discontinue screening , least one week Baseline , throughout 42day study period . f admittance Day 1 final safety evaluation Day 42 . 27 . A drug treatment know cause major organ system toxicity past year . 28 . Caffeinecontaining product excess equivalent 2 cup coffee per day 2 week prior dose final safety evaluation Day 42 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Pharmacokinetic analysis</keyword>
	<keyword>EryDex</keyword>
</DOC>